Brief: Xvivo Perfusion Q1 Adjusted. EBITDA Sek 7.2 Million
April 26 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* Q1 ADJUSTED. EBITDA SEK 7.2 MILLION VERSUS SEK 5.0 MILLION YEAR AGO
* Q1 NET SALES SEK 42.5 MILLION VERSUS SEK 37.5 MILLION YEAR AGO
Source text for Eikon: ID:nWkr7GxKF4
Further company coverage: XVIVO.ST
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength